Skip to main content
LEGN
NASDAQ Life Sciences

Legend Biotech Projects 2026 Operating Profit Amid Strong CARVYKTI® Growth and Pipeline Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$23.32
Mkt Cap
$4.168B
52W Low
$20.21
52W High
$45.297
52W Position info
15% above low
Off High info
49% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

LEGN sits 15% above its 52-week low of $20.21.

Summary

Legend Biotech anticipates achieving operating profit in 2026, driven by the strong market leadership and expanding manufacturing capacity of its flagship CAR-T therapy, CARVYKTI®, alongside promising pipeline advancements.


Key Events · Financing and Capital Events · LEGN

  • Projected Profitability

    The company expects to achieve company-wide operating profit in 2026, marking a significant financial inflection point.

  • CARVYKTI® Market Leadership

    CARVYKTI® has treated over 10,000 patients, achieved NCCN Category 1 designation, and boasts a 10,000 annualized dose capacity by 2026.

  • Pipeline Advancement

    Patients have been dosed for IIT In Vivo CAR-T studies in 2025, with plans to file 1-2 US INDs in the second half of 2026.

  • Manufacturing Scale-Up

    All CARVYKTI® manufacturing sites are now online, with a 97% success rate and a median turnaround time of less than 30 days.


Analysis · LEGN · Life Sciences

Legend Biotech's corporate presentation at the J.P. Morgan Healthcare Conference outlines a robust outlook, projecting company-wide operating profit in 2026. This financial milestone is supported by the strong commercial performance of CARVYKTI®, which has treated over 10,000 patients and achieved NCCN Category 1 designation. The company is also expanding manufacturing capacity and advancing its pipeline, including in vivo CAR-T studies and plans for new INDs, signaling continued innovation and growth.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LEGN was trading at $23.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.2B. The 52-week trading range was $20.21 to $45.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LEGN - Latest Insights

LEGN
Nov 10, 2026, 7:11 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $24.43
Real-time Price: $17.44 info
Change: -$6.99 (-29%) info
Market Cap: $3.394B info
LEGN
Nov 10, 2026, 7:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $23.76
Real-time Price: $17.44 info
Change: -$6.32 (-27%) info
Market Cap: $3.394B info
LEGN
Oct 15, 2026, 8:00 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $19.11
Real-time Price: $17.44 info
Change: -$1.67 (-9%) info
Market Cap: $3.394B info
LEGN
Oct 15, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $19.10
Real-time Price: $17.44 info
Change: -$1.66 (-9%) info
Market Cap: $3.394B info
LEGN
Oct 13, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.10
Real-time Price: $17.44 info
Change: -$0.660 (-4%) info
Market Cap: $3.394B info